Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLargo, Inc. (OTCQX: BLGO) SEC filings page on Stock Titan provides access to the company’s official reports and current disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports describing material events such as contract terminations, legal actions, investor presentations, and equity-related transactions, as well as other periodic and annual filings available through EDGAR.
For a cleantech and life sciences company like BioLargo, SEC filings offer detail on its technology portfolio, licensing and manufacturing agreements, and capital structure that may not appear in press releases alone. Recent 8-K filings, for example, describe the termination of a license and preferred master manufacturing agreement related to pet odor control products, potential impairment of a note receivable, and the filing of a federal lawsuit to protect patented CupriDyne odor control technology. Other 8-Ks discuss investor presentation materials for events such as LD Micro and NobleCon, and the conversion of unpaid salary and expenses by officers into locked-up common stock.
Through this page, users can review BioLargo’s disclosures about material agreements, legal proceedings, financial considerations tied to specific contracts, and corporate actions involving its common stock. Stock Titan enhances this access with AI-powered summaries that help explain the significance of complex filings, including key points from Form 8-K reports and other documents. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track how BioLargo reports on its environmental technologies, medical subsidiaries, licensing relationships, and governance matters over time.
BIOLARGO, INC. Chief Science Officer Kenneth Reay Code received a grant of 69,444 shares of common stock at an acquisition price of $0.162 per share. The award was issued in exchange for reduced salary and unreimbursed business expenses.
The shares are subject to a lock-up agreement and cannot be sold until the company reports at least $40 million in gross revenue for any quarter or year, or its market capitalization exceeds $300 million, or there is a change in control. Following this grant, his total holdings are 25,875,752 shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
BIOLARGO, INC. director Jack B. Strommen received an option grant as compensation for board service. He was awarded an Option to Purchase Common Stock covering 92,593 shares at an exercise price of $0.162 per share, with no cash paid for the grant itself.
The option was issued in lieu of $15,000 in director fees for the most recently completed quarter under the company’s 2024 Equity Incentive Plan. Following this grant, Strommen directly holds derivative securities representing 2,452,103 underlying shares, and this option is scheduled to expire on March 31, 2036.
BIOLARGO, INC. director Christina Elaine Bray received an option grant as compensation for board service. She was awarded an option to purchase 115,741 shares of Common Stock at an exercise price of $0.162 per share, issued under the company’s 2024 Equity Incentive Plan.
The option was granted in lieu of $18,750 of cash fees for the most recently completed quarter. After this award, she beneficially holds derivative securities representing 1,381,502 underlying shares directly, reflecting routine, equity-based director compensation rather than an open-market transaction.
Biolargo, Inc. director Linda Park received a stock option grant as board compensation. On the reported date, she was granted an option to purchase 115,741 shares of common stock at an exercise price of $0.162 per share, expiring on March 31, 2036.
The footnote explains this option was issued in lieu of $18,750 in cash fees for her most recently completed quarterly board service, under Biolargo’s 2024 Equity Incentive Plan. Following this grant, her directly held derivative position is reported as 1,381,502 option-linked shares.
BIOLARGO, INC. director Marshall Dennis E received two option grants for common stock as non-cash compensation. He was granted options over 138,889 shares at an exercise price of $0.162 per share, replacing an earlier option on 68,182 shares that had expired unexercised related to $22,500 in prior services.
He also received a new option over 115,741 shares at the same $0.162 exercise price as payment for $18,750 in board fees for the most recently completed quarter under the 2024 Equity Incentive Plan. After these grants, his reported direct holdings rose to 5,432,829 derivative-linked shares, with both options expiring on March 31, 2036.
BioLargo, Inc. entered into a purchase agreement and related registration rights agreement with Clearthink Capital Partners, LLC that gives BioLargo the right to sell up to $10.0 million of common stock to Clearthink over a 36‑month period, subject to conditions.
After SEC effectiveness of a resale registration statement, BioLargo may, at its sole discretion, direct Clearthink on selected trading days to buy shares in amounts up to the lesser of $500,000 or 300% of the recent average trading value, with a minimum of $25,000 and at least five business days between notices. The purchase price per draw is based on the average of the two lowest closing prices over the prior eight trading days.
As consideration for this committed equity facility, BioLargo issued 500,000 commitment shares of common stock to Clearthink without receiving cash proceeds. Clearthink is capped at 9.99% beneficial ownership and is prohibited from short sales or net short hedging, while BioLargo can terminate the arrangement on one business day’s notice. The initial issuances rely on private offering exemptions under Section 4(a)(2) and Rule 506(b).
BioLargo, Inc. used this report to share an investor slide deck and press release summarizing its 2025 performance and outlook. Management described 2025 as a year of both accomplishment and adversity, including the termination of its largest customer’s license and the related loss of revenue.
The company highlighted a $3.9 million cash balance at year end 2025, a 98% increase in engineering services revenue, and commercialization progress across several business segments. Subsidiaries Clyra Medical Technologies and Cellinity Battery raised capital in 2025, and leadership expressed optimism about 2026 opportunities in surgical products, PFAS water treatment, and battery energy storage.
BioLargo, Inc. reports a difficult 2025, with consolidated revenue of $7,765,000, down 56% from $17,779,000 in 2024, mainly because its largest private‑label odor‑control customer sharply reduced purchases.
The company recorded a net loss of $15,189,000, including a $3,886,000 credit loss expense tied to a customer’s contractual defaults that are now the subject of litigation. Operating cash use was $8,297,000, year‑end cash was $3,883,000, and working capital was $51,000, leading the auditor to highlight substantial doubt about the company’s ability to continue as a going concern.
BioLargo continues investing in cleantech platforms including its AEC PFAS water treatment system, Cellinity™ liquid sodium batteries, and Clyra Medical’s wound‑care products, supported by 34 issued patents and $2,593,000 of R&D spending in 2025, but remains heavily reliant on external equity financing that dilutes existing shareholders.
BioLargo, Inc. reported a new stock option award to its Chief Financial Officer, Charles K. Dargan. On February 1, 2026, he received an option to purchase 300,000 shares of common stock at an exercise price of $0.179 per share. The option becomes exercisable on March 1, 2026 and expires on February 1, 2036. After this grant, he beneficially owned 5,931,668 derivative securities. The filing notes this option was issued as compensation for serving as Chief Financial Officer from February 1, 2026 through January 31, 2027.
BioLargo, Inc. director and Chief Science Officer received 54,803 shares of common stock on 12/31/2025 at an acquisition price of $0.1843 per share. The shares were issued by the company in exchange for a reduction in amounts owed to the reporting person for salary and unreimbursed business expenses.
The newly issued shares are subject to a Lock-Up Agreement that restricts sales until BioLargo reports gross revenue of at least $40 million for any reported period, or its market capitalization exceeds $300 million, or there is a change in control. Following this transaction, the reporting person beneficially owns 25,806,308 shares of BioLargo common stock, including 22,139,012 shares held indirectly through a wholly owned corporation.